Testing effectiveness (Phase 2)Study completedNCT00910858
What this trial is testing
A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic Syndromes
Who this might be right for
Low- or Intermediate-1-risk Myelodysplastic Syndrome (MDS)
Celgene Corporation 40